Brief Summary:
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator’s choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Condition or disease
Intervention/treatment
Phase
Neoplasms, Ovarian
Drug: MORAb-202 Drug: Paclitaxel Drug: Pegylated Liposomal Doxorubicin (PLD) Drug: Topotecan
Phase 2
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
